Skip to contentV
Valion Bio, Inc.
V
VBIOValion Bio, Inc. Q2 2026 · 10-Q
Revenue—
Net Income-$7.10M-$7.10MN/M vs Q2 2025 EPS, diluted—
Operating Income-$6,424,000N/M Operating Cash Flowderived-$5,281,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Valion Bio, Inc. · CIK 1787740 · Engraved from SEC EDGAR
Free Cash Flowderived-$5,338,000N/M ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end